XURIDEN Drug Patent Profile

When do Xuriden patents expire, and when can generic versions of Xuriden launch?

Xuriden is a drug marketed by Btg Intl and is included in one NDA.

The generic ingredient in XURIDEN is uridine triacetate. There are thirty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the uridine triacetate profile page.

Summary for XURIDEN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	73
Patent Applications:	330
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for XURIDEN
What excipients (inactive ingredients) are in XURIDEN?	XURIDEN excipients list
DailyMed Link:	XURIDEN at DailyMed

See drug prices for XURIDEN

Pharmacology for XURIDEN

Ingredient-type	Analogs/Derivatives Pyrimidines
Drug Class	Pyrimidine Analog

Anatomical Therapeutic Chemical (ATC) Classes for XURIDEN

A16AX	Various alimentary tract and metabolism products
A16A	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A	Alimentary tract and metabolism

US Patents and Regulatory Information for XURIDEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Btg Intl	XURIDEN	uridine triacetate	GRANULE;ORAL	208169-001	Sep 4, 2015		RX	Yes	Yes

Expired US Patents for XURIDEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Btg Intl	XURIDEN	uridine triacetate	GRANULE;ORAL	208169-001	Sep 4, 2015

International Patents for XURIDEN

See the table below for patents covering XURIDEN around the world.

Country	Patent Number	Title	Estimated Expiration
China	1071577
Japan	2008007525	PYRIMIDINE NUCLEOTIDE PRECURSOR FOR TREATMENT OF SYSTEMIC INFLAMMATION AND INFLAMMATORY HEPATITIS
Israel	114887
Norway	892642
Russian Federation	2203669	СПОСОБЫ ЛЕЧЕНИЯ СЕПСИСА И ВОСПАЛЕНИЙ С ПОМОЩЬЮ ОКСИПУРИНОВЫХ НУКЛЕОЗИДОВ (METHOD FOR TREATING SEPSIS AND INFLAMMATIONS DUE TO OXYPURINE NUCLEOSIDES)
European Patent Office	0339075	ACYLATED URIDINE AND CYTIDINE AND USES THEREOF

Supplementary Protection Certificates for XURIDEN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1849470	2017/033	Ireland		PRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160425
2207786	2023C/550	Belgium		PRODUCT NAME: CEDAZURIDINE, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1756 20230918
2207786	LUC00326	Luxembourg		PRODUCT NAME: COMPOSITION COMPRENANT: DE LA CEDAZURIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; ET DE LA DECITABINE; AUTHORISATION NUMBER AND DATE: EU/1/23/1756 20230913
2207786	LUC00327	Luxembourg		PRODUCT NAME: CEDAZURIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/23/1756 20230918
1849470	300889	Netherlands		PRODUCT NAME: TRIFLURIDINE IN COMBINATIE MET TIPIRACILHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160427
2207786	301256	Netherlands		PRODUCT NAME: CEDAZURIDINE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/23/1756 20230918